13.61
-2.54 (-15.73%)
| Previous Close | 16.15 |
| Open | 14.90 |
| Volume | 112,377 |
| Avg. Volume (3M) | 33,890 |
| Market Cap | 4,993,481,216 |
| Price / Earnings (TTM) | 151.22 |
| Price / Earnings (Forward) | 62.11 |
| Price / Sales | 11.99 |
| Price / Book | 16.03 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 |
| Profit Margin | 6.37% |
| Operating Margin (TTM) | 8.46% |
| Diluted EPS (TTM) | 0.090 |
| Quarterly Revenue Growth (YOY) | 48.80% |
| Quarterly Earnings Growth (YOY) | 3.80% |
| Total Debt/Equity (MRQ) | 102.33% |
| Current Ratio (MRQ) | 2.78 |
| Operating Cash Flow (TTM) | 43.03 M |
| Levered Free Cash Flow (TTM) | 72.81 M |
| Return on Assets (TTM) | 5.32% |
| Return on Equity (TTM) | 13.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Telix Pharmaceuticals Limited | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 4.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 1.75 |
|
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |